ANXA2 and neoplasm: Once ANXA2 binds to fibrinogen and tissue-type fibrinogen activators, it can activate metalloproteinase (MMPs), which will in turn disrupt the integrity of the extracellular matrix, resulting in tumour invasion and metastasis (Xu et al., 2015).